Microglia Replacement via CSF1R Inhibition and HSCT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for microglia replacement in the brain following hematopoietic stem cell transplantation (HSCT) are inefficient and variable, with low and inconsistent chimerism, and require genetic modification or extensive pre-conditioning, limiting their therapeutic effectiveness for neurological disorders.
Innovation Solution
A method involving HSCT combined with pharmacological inhibition of the CSF1R pathway using PLX5622 to deplete endogenous microglia, allowing efficient engraftment and differentiation of circulation-derived myeloid cells (CDMCs) into microglia-like cells throughout the brain, achieving high and stable chimerism without the need for genetic modification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HSCT methods are used for microglia replacement, then exogenous stem cells are introduced to the patient, but the chimerism level is low and variable with inefficient replacement
Solution Approach 1:
The patent applies preliminary action by administering a microglial cell conditioning agent (CSF1R inhibitor) before or during the HSCT procedure to deplete endogenous microglia in advance. This pre-conditioning creates space and reduces competition, allowing exogenous stem cells to engraft more efficiently and achieve high, stable chimerism levels without requiring genetic modification
Solution Approach 2:
The patent changes the biochemical parameter of the microglial niche by introducing a CSF1R inhibitor that blocks the colony stimulating factor 1 signaling pathway. This parameter change (inhibiting CSF1R signaling) leads to depletion of endogenous microglia and creates favorable conditions for exogenous cell engraftment, transforming the microglial cell population dynamics
2Reliability
If genetic modification or extensive pre-conditioning is applied to improve microglia replacement, then cell function can be enhanced, but the procedure complexity and patient burden increase
Solution Approach 1:
The patent extracts the requirement for genetic modification and extensive pre-conditioning by using a pharmacological approach instead. By taking out the need for complex genetic engineering procedures and replacing it with a drug-based CSF1R inhibition strategy, the method achieves high therapeutic effectiveness while significantly reducing procedure complexity and patient burden
Solution Approach 2:
The patent substitutes mechanical and procedural complexity (genetic modification, extensive conditioning) with a biochemical mechanism (CSF1R inhibition). This replacement transforms a mechanically complex process into a simpler pharmacological intervention that achieves the same therapeutic goal of efficient microglia replacement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in near complete replacement of microglia with CDMCs, demonstrating enhanced regenerative capacity and stability, with CDMCs acquiring a microglia-like phenotype and function, offering a promising platform for therapeutic microglia-replacement therapies for neurological disorders.
Implementation Method 1
pharmacological inhibition of the CSF1R pathway using PLX5622 to deplete endogenous microglia
Implementation Method 2
allowing efficient engraftment and differentiation of circulation-derived myeloid cells (CDMCs) into microglia-like cells
Data Source
AI summary
Methods are provided for the efficient replacement of endogenous microglia with circulation-derived cells derived from the bone marrow in an individual, the method comprising hematopoietic stem cell transplantation, and upregulation of CDMC repopulation, wherein (i) endogenous hematopoietic stem cells are ablated, (ii) exogenous hematopoietic stem cells are introduced to the patient; and (iii) a glial cell conditioning agent is administered to enhance replacement of endogenous microglia with circulation-derived cells.